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Acute glucose dysmetabolismThough age is a predictor of adverse events after acute coronary syndrome, including in-hospital and post-
hospital mortality rates, elderly patients are under-represented in randomized trials evaluating strategies of
early coronary revascularization in acute myocardial infarction.
Several factors can account for the unfavorable outcome of the elderly, comprising increased glucose values.
Diabetes is more common in the elderly patients with acute myocardial infarction in respect to younger
patients and elevated glucose, though common, are rarely treated and associated with increased mortality,
particularly in those without recognized diabetes.
Age itself is thought to affect the acute glucose response to stress. Human aging is associated with impaired
β-cell sensitivity to glucose and impaired β-cell compensation to insulin resistance and older people exhibit
an impaired glucose response after injury characterized by a more marked increases in endogenous glucose
production.
In the early phase of ST elevation myocardial infarction (STEMI), the acute glucose response to stress
comprises not only hyperglycemia but also insulin-resistance (assessed by the Homeostatic Model
Assessment). Recently it has been documented in 346 STEMI patients submitted to mechanical
revascularization that the acute glucose response to myocardial injury differs in respect to age, since older
patients showed the highest glucose levels and the poorest glycemic control during ICCU stay in the lack of
differences in insulin resistance incidence.
Taking into account that aging impairs the acute glucose response to stress in elderly STEMI patients, further
studies are needed to establish whether a different (more aggressive) therapeutic regime is needed in this
subgroup of patients at higher risk.Ltd. All rights reserved.
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The elderly are the fastest growing segment of our population and
coronary artery disease is a leading cause of mortality and morbidity
in this subgroup of patients [1,2]. Though age is a predictor of adverse
events after acute coronary syndrome, including in-hospital and post-
hospital mortality rates [3–5], elderly patients are under-represented
in randomized trials evaluating strategies of early coronary revascu-
larization in acute myocardial infarction [6] and we are often forced to
extrapolate the existing evidence and guidelines while treating the
elderly [7].
Claessen et al. [8] recently reported an increasing proportion of
octogenarians treated with primary PCI from 1997 to 2007, who
showed increased short and long-term mortality when compared to
younger patients. This finding is in keeping with earlier clinical trialssuch as GISSI-2 and GUSTO-1 [9,10] as well as with previous studies
in the era of mechanical revascularization by others [11–16] and
us [17].
Several factors can account for the unfavorable outcome of the
elderly: structural and functional changes in the cardiovascular
system with aging, atypical symptoms (inducing a delay in seeking
medical care) and higher co-morbidities, including increased glucose
values. In fact, the elderly have a high prevalence of unrecognized and
established diabetes [18] and diabetes is more common in the elderly
patients with acute myocardial infarction (AMI) in respect to younger
patients [17,19–21]. In the Cooperative Cardiovascular Project (CCP),
a nationally representative, community-based sample of elderly
patients hospitalized with AMI [22], elevated glucose was common,
rarely treated and associated with increased mortality, particularly in
those without recognized diabetes.
In the present manuscript we are going to focus on the available
evidence on the acute glucose dysmetabolism in elderly patients in
the early phase of ST elevation myocardial infarction submitted to
mechanical revascularization.th ST elevation myocardial infarction submitted to
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In healthy subjects, despite large timely fluctuations in supply and
demand, in a fasting state, plasma glucose levels are normally regulated
within a narrow range between 80 and 125 mg/dl. Interestingly, 80% of
systemic glucose utilization occurs by non-insulin mediated glucose
uptake under basal conditions, mainly by the central nervous system
[23]. Glucose transport into cells occurs as facilitated diffusion using
one of the five glucose transported (GLUT) channel proteins (GLUT1-
mediated insulin independent transport mostly in basal conditions;
GLUT4 specifically and reversibly upregulated by insulin). During
moderate hyperglycemia, cells usually respond with an internationali-
zation of GLUT transport molecules to protect themselves from glucose
overload [24]. In the heart, oxidation of FFAs is the preferred source of
energy in the resting aerobic state; FFAs are taken up into the cardiac
mitochondria where they undergo beta-oxidation. Carbohydrate me-
tabolism, representing a relative minor source of ATP in normal
myocardium, involves a glycolytic component followed by production
of acetyl–CoA from pyruvate and entry into the Krebs cycle [25].
The stress imposed by any type of acute illness leads to the
development of insulin resistance, glucose intolerance and hypergly-
cemia [26]. In the acute phase of critical illness, despite high plasma
glucose levels and abundantly released insulin, hepatic glucose
production is upregulated probably due to elevated levels of
cytokines, growth hormone, glucagons and cortisol [27–29]. Hepatic
glycogenolysis is further enhanced by catecholamines which also
inhibit glycogenesis [29]. Glucose uptake in heart, skeletal muscle,
and adipose tissue is compromised because of impaired insulin-
stimulated glucose uptake by the glucose transporter 4 (GLUT4) and
impaired glycogen synthase [25]. Nevertheless it has been observed
that the total body glucose uptake is massively increased but it is
accounted for by tissues that do not depend on insulin for glucose
uptake such as brain and blood cells [30]. The higher levels of insulin,
impaired peripheral glucose uptake and elevated hepatic glucose
production reflect the development of insulin resistance during critical
illness.
In the setting of acute coronary syndrome (ACS), acute hypergly-
cemia is associated with adverse metabolic effects that may
contribute to a poor outcome [31].
Myocardial ischemia results in an increased rate of glycogen break-
down and glucose uptake via translocation of glucose transporter-4
receptors to the sarcolemma [32]. This adaptive mechanism is
important because glucose oxidation requires less oxygen than FFA
oxidation tomaintain adenosine triphosphate (ATP) production so that
myocardial energetics is more efficient during the increased depen-
dence on glucose oxidation. With relative insulinopenia (insulin
resistance or frank diabetes) exacerbated by the stress of ACS, the
ischemic myocardium is forced to utilize FFAs more than glucose for an
energy source because myocardial glucose uptake is acutely impaired.
Thus, the hypoxic myocardium becomes less energy efficient in the
setting of frank diabetes or insulin resistance, as FFA oxidation results
in the generation of fewer ATP molecules per molecule of oxygen as
compared with glucose oxidation. Catecholamine release with stress
further stimulates the release of FFAs, which may contribute to
myocardial damage and arrhythmia risk by increasing oxygen demand
and oxidative stress [33,34]. During myocardial ischemia, high
concentration of FFAs increases myocardial oxygen requirement,
depresses myocardial activity and contraction, impairs calcium homeo-
stasis and increases the production of free radicals [35]. During
reperfusion, since FFA oxidation quickly recovers and dominates as
the source of energy, there is a marked inhibition of glucose inhibition.
Consequently, high glycolitic rates (probably due to increased glucose
transport) and lowglucose oxidation rates can result in a substantial rise
of non-oxidative glucose disposal. The uncoupling of glycolysis from
glucose oxidation may lead to the production of protons from glucose
metabolism during reperfusion, thus exacerbating the ischemic injury.Please cite this article as: Lazzeri C, et al, Acute glucose dysmetabolism
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Acute insulin resistance is known to be part of the glyco-metabolic
response to stress [36], but few studies assessed the role of insulin
resistance, evaluated by means of Homeostatic Model Assessment
(HOMA index), in the early phase of acute myocardial infarction
[37,38].
HOMA index reflects basal insulin sensitivity and responsiveness
[39]; it has been firstly proposed for the assessment of insulin
resistance [30] in stable patients, but it has been recently used to
estimate insulin resistance in critically ill patients with acute renal
failure [40]. In a group of 30 critically ill medical patients (continu-
ously sedated and ventilated), Holzinger et al. [41], documented that
HOMA index, though indicating insulin resistance, did not correlated
with the M-values and concluded that the euglycemic hyperinsu-
linemic clamp, which reflects stimulated insulin sensitivity, remains
the gold standard technique in critically ill patients. However,
euglycemic hyperinsulinemic clamp is time consuming, labor inten-
sive and requires an experienced operator to manage the technical
difficulties, so it is known to be not appropriate for routine clinical
applications [40].
In 168 consecutive patients with acute myocardial infarction but
without previously known diabetes, Wallander et al. [37] evaluated
glucose abnormalities by means of HOMA index (assessed on day 1
after admission) and OGTT (performed on the day of hospital
discharge (day 4 or 5)). The Authors documented that in these
patients glucose abnormalities are quite common and can be to a
significant extent related to impaired beta cell secretion of insulin.
They supposed that hyperglycemia immediately after an infarction
cannot be considered mainly a stress epiphenomenon but it may
reflect a stable disturbance of glucose regulation preceding the event.
In the era of mechanical reperfusion, Nishio et al. [38] identified, by
means of HOMA index two different subgroups among 61 nondiabetic
MI patients: the non-insulin resistant (IR) group and the insulin
resistant group which consisted of transient IR, which correlated with
stress hormones, and the continuous IR, which correlated with leptin
(associated with endothelial dysfunction) thus contributing to re-
stenosis after coronary stenting at 4 month follow-up.
We recently documented, in 253 nondiabetic STEMI patients
submitted to mechanical revascularization, that insulin-resistance, as
assessed by HOMA index proved to be an independent predictor for
in-hospital mortality. Insulin-resistance was quite common in
nondiabetic STEMI patients, since it affected more than half of the
population. In our series nondiabetic STEMI patients with insulin-
resistance exhibited a larger infarct size (as inferred by higher values
of cardiac enzymes) and a more severe metabolic derangement (as
indicated by NT-proBNP and lactic acid levels) [42].
4. Aging and acute glucose dysmetabolism
Previous studies, mainly performed in normal subjects [43,44],
documented that human aging is associated with impaired β-cell
sensitivity to glucose and impaired β-cell compensation to insulin
resistance. Several factors can account for this phenomenon, such as
lower insulin secretion and serum insulin responses to glucose. Aging
could be associated with loss of β-cell mass or simply impaired
function of a preserved β-cell mass or a combination of these two
factors. Alterations in visceral adiposity and lipid parameters such as
free fatty acids and triglycerides associated with age-related changes
in body composition and increased adiposity could also be playing a
role [43]. It has also been documented that older people exhibit an
impaired glucose response after injury characterized by a more
marked increases in endogenous glucose production [44]. In trauma
patients, age was associated with an increase in serum glucose (also
related to degree of injury as reflected in Glasgow Coma Scale on
admission and Injury Severity Score subsequently) but not within the elderly with ST elevation myocardial infarction submitted to
011.01.075
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and middle-aged trauma patients is thought to reflect a predomi-
nance of β-adrenergic activity [46] and it could contribute to the
observed differences in the insulin responses of young and older
trauma patients.
Few studies investigated the relation between hyperglycemia
and cardiovascular disease in elderly patients and results are quite
intriguing.
Recently Crandall et al. [47] observed that older adults with post-
challenge hyperglycemia experience significant fasting and post-
prandial metabolic dysregulation, which is accompanied by a pro-
atherosclerotic and pro-thrombotic vascular profile. In elderly
patients admitted to a sub-intensive care unit [48], newly recognized
hyperglycemia was associated with a higher mortality rate than in
those with a prior history of diabetes.
In the CCP [22], in a large nationally representative study of
141,680 elderly AMI patients, the relationship between admission
glucose and mortality was different in patients with and without
recognized diabetes, elevated glucose was associated with a steep
linear mortality increase in patients without recognized diabetes, but
not in diabetic patients, except at severe levels of hyperglycemia. The
authors suggested several explanations for this phenomenon. Some
hyperglycemic AMI patients without a history of diabetes could have
been true diabetics, neither diagnosed nor adequately managed.
Hyperglycemic patients without recognized diabetes could have been
treated with insulin less frequently than those with established
diabetes. An underlying insulin-resistance could have been present
in a substantial proportion of hyperglycemic patients without
recognized diabetes. The CCP, though retrospective, strengthens the
prognostic value of admission glucose and its utility in risk strati-
fication in elderly STEMI patients. In this study population, STEMI
accounted for about one-third (29.2%) and PCI was performed in the
9.9% of patients [22].
While Kosiborod et al. [22] observed that elevated glucose is
associated with increased mortality in elderly acute myocardial
infarction, the same group of investigators [49] did not find any
significant association between admission glucose levels and mortality
in a large cohort of elderly patients hospitalized with heart failure
suggesting that the relationship between hyperglycemia and adverse
outcomes seen in acute myocardial infarction cannot be automatically
extended to patients hospitalized with other cardiovascular conditions.
These discrepancies may be related to the differences in age
response to metabolic stress in acute and chronic conditions. In
particular it has been observed in animal models, that with age, there
is a loss of plasticity in physiological adaptive response mechanisms
associated with metabolic responses to stress [50].
5. Aging and acute insulin-resistance
Chang et al. [51] in a retrospective analysis, examined the HOMA
model in comparison with dynamic testing of insulin sensitivity and
β-cell function with the frequently sampled i.v. glucose tolerance test
in a large cohort of both older men and women with normal and
impaired glucose tolerance. HOMA measures of insulin resistance
were able to detect increased insulin resistance in older people with
impaired glucose tolerance, though overall agreement between
HOMA and the frequently sampled i.v. glucose tolerance test was
moderate. The authors concluded that HOMA may detect age-related
insulin resistance when comparing large populations of older people,
though dynamic testing appears to be necessary to quantitate
diminished insulin secretion in older people.
We recently investigated [52] the interaction between age and
glucose metabolism response in the acute phase of patients with
STEMI without previously known diabetes in 346 STEMI patients
consecutively admitted to our Intensive Cardiac Care Unit (ICCU) after
primary percutaneous coronary intervention (PCI). We observed that,Please cite this article as: Lazzeri C, et al, Acute glucose dysmetabolism
mechanical revascularization, Int J Cardiol (2011), doi:10.1016/j.ijcard.2the very old patients (aged N79 yrs) exhibited the highest values of
glycemia and peak glycemia, together with lowest values of insulin,
while the incidence of insulin resistance (as inferred by HOMA index)
remained unchanged across the age subgroups. Very old STEMI patients
also showed a more marker inflammatory activation (as inferred by
Erythrocyte Sedimentation Rate – ESR – and fibrinogen values) which
may contribute for the increased glucose values, even if it cannot be
ruled out that the elevation of ESR in the older patientsmight be related
to a possible higher prevalence of anemia in thesepatients,whichagrees
with the observed decrease in the renal function. It is interesting to
note that infarct size (as inferred by Tn I values) was not significantly
different among age groups. We further confirm that elderly STEMI
patients show an increased in-hospital mortality as well as increased
values of NT-proBNP. We concluded that the acute glucose response to
myocardial injury differs in respect to age, since older patients showed
the highest glucose levels and the poorest glycemic control during ICCU
stay in the lack of differences in insulin resistance incidence. These
findingswere confirmed after exclusionof patientswith apoor glycemic
control in the previous 2–3 months (that is patientswithHbA1c N6.5%).
6. Acute glucose management in elderly STEMI patients
The complexity of the glyco-metabolic response to stress during
acute myocardial infarction, as well as the scarcity of data on this
topic, can be inferred by still existing controversies on how to manage
increased glucose values in patients with acute coronary syndromes,
even in the elderly. According to recent guidelines [53], it is reason-
able to consider intensive glucose control in patients with significant
hyperglycemia (that is plasma glucose N180 mg/dl), but strategies for
the management of patients with milder degrees of hyperglycemia
are far to be elucidated. We recently [54] observed that in nondiabetic
STEMI patients the poorer in-hospital glucose control was associated
with highermortality; peak glycemia N180 mg/dl was associated with
the highest mortality, whereas patients with peak glycemia com-
prised between 140 and 180 mg/dl exhibited intermediate mortality
rates. In a previous paper [42] we documented that the elderly STEMI
patients exhibited the poorest glycemic control during ICCU stay (as
inferred by peak glycemia).
Taking into account that aging impairs the acute glucose response
to stress in elderly STEMI patients, further studies are needed to
establish whether a different (more aggressive) therapeutic regime is
needed in this subgroup of patients at higher risk. Moreover, no
recommendation is so far available on whether (and, if so, how) to
treat STEMI insulin-resistant patients.
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